Top Markets
#1 Status Status +15.88%
#2 Animecoin Animecoin +4.71%
#3 Hex Trust USD Hex Trust USD +4.51%
#4 MANTRA MANTRA +2.96%
#5 Raydium Raydium +2.65%
#6 Infinity Ground Infinity Ground +2.33%
#7 Holo Holo +2.24%
#8 OmniBridge Bridged Zcash (Solana) OmniBridge Bridged Zcash (Solana) +2.03%
#9 City Boy City Boy +1.97%
#10 Zcash Zcash +1.90%
Coin of the day
Status Status
設定
言語
日本
通貨
USD
テーマ
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
株式のランク #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
株価
$451.59
時価総額
$114.70B
変化（1日）
-2.36%
変化（1年）
-11.89%
国
US
取引 Vertex Pharmaceuticals Incorporated (VRTX)

カテゴリー

Healthcare
Vertex Pharmaceuticals Incorporated（VRTX）の発行済株式数
December 2025 時点の発行済株式数 253.90M
Vertex Pharmaceuticals Incorporated の最新の財務報告および株価によると、現在の発行済株式数は 253.90M です。December 2024 の終わりには、同社は 257.50M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Vertex Pharmaceuticals Incorporated（VRTX）の発行済株式数の履歴（2000 ～ 2026）
各年末時点の発行済株式数
年 発行済株式数 変化
2026 (TTM) 253.90M -0.70%
2025 255.70M -0.70%
2024 257.50M -0.08%
2023 257.70M 0.62%
2022 256.10M -0.62%
2021 257.70M -0.82%
2020 259.84M 1.21%
2019 256.73M 0.96%
2018 254.29M 2.18%
2017 248.86M 2.16%
2016 243.59M 1.14%
2015 240.84M 2.52%
2014 234.92M 4.49%
2013 224.83M 6.08%
2012 211.95M 3.44%
2011 204.89M 2.24%
2010 200.40M 15.67%
2009 173.26M 23.27%
2008 140.56M 8.97%
2007 128.99M 13.92%
2006 113.22M 26.87%
2005 89.24M 13.58%
2004 78.57M 2.03%
2003 77.00M 1.66%
2002 75.75M 1.73%
2001 74.46M 10.02%
2000 67.68M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数 差 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 1,651.81%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -59.47%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -25.17%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 90.46%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M -75.81%
NL